40 Participants Needed

New Dressing for Burns

MG
Overseen ByMarc G Jeschke, MD PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Hamilton Health Sciences Corporation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The goal of this clinical trial is to test a novel donor site dressing called Product X in burn patients requiring skin grafting procedures. A donor site is an area where the surgeon has taken a layer of skin to create a graft. This is required to make severe burn wounds heal. However, donor sites often experience infection, pain, and itch that can delay the healing of the donor site. To prevent these complications, donor sites are covered with dressings to prevent infection and absorb fluids from the wounds. Many options exist, but no single dressing is best, especially for pain management and the ability to absorb fluids from wounds effectively. The investigators have developed a new donor site dressing to meet the criteria of an "ideal dressing," called Product X. The main question this clinical trial aims to determine the safety and potential wound-healing benefits of this donor site dressing as a new therapy that will help patients who require donor sites. Participants will: * Be randomized, like a flip of a coin, to receive either Product X or the standard-of-care dressings. If patients have one donor site, it will be randomized to receive either Product X or the standard-of-care dressings, Allevyn and Xeroform. If they have two donor sites, one donor site will be randomized to receive Product X and the other to receive standard-of-care dressings. * Have photographs of their donor sites taken at the operation, during dressing changes, at discharge, and at regularly scheduled outpatient follow-up appointments with the burn clinic. * Complete short questionnaires to assess their comfort (pain and itch) with their donor sites daily. * Complete a scar formation questionnaire at your regularly scheduled follow-up appointments in the outpatient burn clinic. Researchers will compare Product X to standard-of-care dressings (Allevyn and Xeroform) to see if there are improvements in wound healing, pain, itch, and infection.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

How does the new dressing for burns differ from other treatments?

The new dressing, Aquacel Ag, is unique because it is a silver-containing hydrofiber that releases silver for up to two weeks, promoting a healing environment and requiring fewer dressing changes compared to other treatments. This reduces pain and is easy to apply, making it particularly beneficial for managing partial-thickness burns in children.12345

Research Team

MG

Marc G Jeschke, MD PhD

Principal Investigator

Hamilton Health Sciences Corporation

Eligibility Criteria

This trial is for adults over 18 with deep burns covering less than a quarter of their body, needing skin grafts from their thigh, torso, or arm. It's not for those at the end of life, pregnant women, or active cancer patients under treatment.

Inclusion Criteria

Less than 25% of my body has been burned.
I have suitable tissue on my thigh, torso, or arm for donation.
I have a severe burn that needs surgery.

Exclusion Criteria

Patients who are moribund
Pregnancy
I am currently receiving treatment for my active cancer.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either Product X or standard-of-care dressings, with photographs and questionnaires completed during dressing changes and at discharge.

Up to 52 weeks
Regular visits for dressing changes and assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment, including scar formation and healing assessments at 3 and 6 months post-discharge.

6 months
Follow-up appointments at 3 and 6 months

Treatment Details

Interventions

  • Product X
  • Standard-of-Care
Trial Overview The study tests Product X against standard dressings (Allevyn and Xeroform) in managing donor sites after skin grafting. Participants are randomly assigned to either Product X or standard care and monitored through photos, daily comfort surveys, and scar assessments.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Product XExperimental Treatment1 Intervention
Group II: Standard-of-CareActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hamilton Health Sciences Corporation

Lead Sponsor

Trials
380
Recruited
345,000+

References

A silver-sulfadiazine-impregnated synthetic wound dressing composed of poly-L-leucine spongy matrix: an evaluation of clinical cases. [2013]
Aquacel ag® in paediatric burns - a prospective audit. [2021]
Silver containing hydrofiber dressing promotes wound healing in paediatric patients with partial thickness burns. [2018]
The local treatment and available dressings designed for chronic wounds. [2018]
Effectiveness of bridge V.A.C. dressings in the treatment of diabetic foot ulcers. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security